MX2009004295A - Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa. - Google Patents

Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.

Info

Publication number
MX2009004295A
MX2009004295A MX2009004295A MX2009004295A MX2009004295A MX 2009004295 A MX2009004295 A MX 2009004295A MX 2009004295 A MX2009004295 A MX 2009004295A MX 2009004295 A MX2009004295 A MX 2009004295A MX 2009004295 A MX2009004295 A MX 2009004295A
Authority
MX
Mexico
Prior art keywords
prepare
pharmaceutical composition
indazolemethoxyalkanoic
acid
indazolemethoxyalkanoic acid
Prior art date
Application number
MX2009004295A
Other languages
English (en)
Spanish (es)
Inventor
Angelo Guglielmotti
Giuseppe Biondi
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of MX2009004295A publication Critical patent/MX2009004295A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mixers Of The Rotary Stirring Type (AREA)
MX2009004295A 2006-11-24 2007-11-13 Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa. MX2009004295A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002254A ITMI20062254A1 (it) 2006-11-24 2006-11-24 Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
PCT/EP2007/009908 WO2008061671A2 (en) 2006-11-24 2007-11-13 Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels

Publications (1)

Publication Number Publication Date
MX2009004295A true MX2009004295A (es) 2009-05-05

Family

ID=38198404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004295A MX2009004295A (es) 2006-11-24 2007-11-13 Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.

Country Status (23)

Country Link
US (2) US8198310B2 (enExample)
EP (2) EP2409698B1 (enExample)
JP (1) JP5192490B2 (enExample)
KR (1) KR101413616B1 (enExample)
CN (1) CN101541323B (enExample)
AR (1) AR063894A1 (enExample)
AU (1) AU2007323351B2 (enExample)
BR (1) BRPI0718522A2 (enExample)
CA (1) CA2666371C (enExample)
CY (1) CY1116664T1 (enExample)
DK (2) DK2409698T3 (enExample)
EA (1) EA016885B1 (enExample)
ES (2) ES2403584T3 (enExample)
GE (1) GEP20125570B (enExample)
IL (1) IL198286A (enExample)
IT (1) ITMI20062254A1 (enExample)
MX (1) MX2009004295A (enExample)
PL (2) PL2097080T3 (enExample)
PT (2) PT2097080E (enExample)
SG (1) SG176508A1 (enExample)
SI (2) SI2097080T1 (enExample)
UA (1) UA97123C2 (enExample)
WO (1) WO2008061671A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
GEP20135879B (en) 2009-08-03 2013-07-10 Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It Method of 1-benzyl-3-hydroxymethyl-1h-indazole preparation, derivatives thereof, and required magnesium intermediates
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
JP6625064B2 (ja) * 2014-05-15 2019-12-25 トランスレイタム メディカス インコーポレイテッド 眼障害を治療かつ診断するための組成物および方法
EP3990433A4 (en) 2019-06-25 2023-07-26 Translatum Medicus Inc. METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES
CA3184282A1 (en) 2020-06-27 2021-12-30 Emre Koyuncu Composition of compounds that modulate cell metabolism and methods of use
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131779B (it) * 1980-07-29 1986-06-25 Acraf Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
US6077539A (en) * 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
IT1293794B1 (it) 1997-07-28 1999-03-10 Acraf Farmaco attivo nel ridurre la produzione di proteina mcp-1
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
CA2755452C (en) * 1998-02-02 2013-09-10 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
CA2605900A1 (en) 2005-04-29 2006-11-09 Nycomed Gmbh Mutual prodrug compounds for use as antiinflammatory agents with gastrointestinal protective activity
WO2007062469A1 (en) * 2005-12-01 2007-06-07 Flinders Technologies Pty Ltd Methods and compositions for preventing and/or treating pancreatitis
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca

Also Published As

Publication number Publication date
HK1165275A1 (en) 2012-10-05
EP2097080B1 (en) 2013-02-20
GEP20125570B (en) 2012-07-10
PL2409698T3 (pl) 2015-06-30
CY1116664T1 (el) 2017-03-15
AU2007323351B2 (en) 2013-05-02
PT2097080E (pt) 2013-04-01
US8846745B2 (en) 2014-09-30
JP2010510263A (ja) 2010-04-02
US8198310B2 (en) 2012-06-12
EP2097080A2 (en) 2009-09-09
SI2097080T1 (sl) 2013-05-31
CN101541323B (zh) 2012-01-04
EP2409698A1 (en) 2012-01-25
HK1129071A1 (en) 2009-11-20
CN101541323A (zh) 2009-09-23
US20100069456A1 (en) 2010-03-18
SI2409698T1 (sl) 2015-04-30
KR101413616B1 (ko) 2014-07-01
EA200970506A1 (ru) 2009-10-30
AR063894A1 (es) 2009-02-25
AU2007323351A1 (en) 2008-05-29
UA97123C2 (uk) 2012-01-10
KR20090081410A (ko) 2009-07-28
EA016885B1 (ru) 2012-08-30
ES2403584T3 (es) 2013-05-20
ES2530623T3 (es) 2015-03-04
WO2008061671A2 (en) 2008-05-29
IL198286A (en) 2016-03-31
CA2666371C (en) 2014-05-06
BRPI0718522A2 (pt) 2013-11-12
JP5192490B2 (ja) 2013-05-08
ITMI20062254A1 (it) 2008-05-25
EP2409698B1 (en) 2015-01-21
WO2008061671A3 (en) 2008-11-27
DK2097080T3 (da) 2013-05-21
IL198286A0 (en) 2010-02-17
SG176508A1 (en) 2011-12-29
PL2097080T3 (pl) 2013-07-31
DK2409698T3 (en) 2015-04-27
CA2666371A1 (en) 2008-05-29
US20120283307A1 (en) 2012-11-08
PT2409698E (pt) 2015-02-10

Similar Documents

Publication Publication Date Title
MX2011012122A (es) Derivados de tiofeno.
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
TW200833663A (en) Therapeutic agents
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
IL213613A (en) History of pirazine, preparations containing them and their uses
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
UA92637C2 (en) Pyridine[3,4-b]pyrazinones
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
TW200716628A (en) Novel compounds
MX2009004295A (es) Uso de un acido indazolmetoxialcanoico para reducir niveles de triglicerido, colesterol y glucosa.
TNSN07419A1 (en) Methods for treating drug resistant cancer
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
WO2011047055A8 (en) Novel mek inhibitors, useful in the treatment of diseases
WO2006077025A3 (en) Morpholines as 5ht2c agonists
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
TW200800993A (en) Organic compounds
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases

Legal Events

Date Code Title Description
FG Grant or registration